Nitrofurantoin and congenital abnormalities
- 作者：Czeizel ; Andrew E. ; Rockenbauer ; Magda ; Sø ; rensen ; Henrik T. ; Olsen ; Jø ; rn
- 关键词：Nitrofurantoin ; Human teratogenic potential ; Congenital abnormalities ; Case-control analysis
- 刊名：European Journal of Obstetrics and Gynecology and Reproductive Biology
- 出版年：2001
- 期刊代码：92_03012115
- 类别：med
- 出版时间：March, 2001
- 卷：95
- 期：1
- 页码：119-126
- 文件大小：167 K
摘要
Objective: To study human teratogenic potential of oral nitrofurantoin treatment during pregnancy. Materials and Methods: Pair analysis of cases with congenital abnormalities and matched population controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980–1996. Results: Of 38,151 pregnant women who had newborn infants without any congenital abnormalities (population control group), 774 (3.4%); of 22,865 case pregnant women who had newborns or fetuses with congenital abnormalities, 1079 (2.8%) and of 812 pregnant women who had newborns or fetuses with Down’s syndrome (patient controls), 23 (2.8%) pregnant women were treated with nitrofurantoin. The above differences between population controls and cases may be connected with recall bias, because the case-control pair analysis did not indicate a teratogenic potential of nitrofurantoin use during the second and the third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with nitrofurantoin during pregnancy does not present detectable teratogenic risk to the fetus.